Showing 391-400 of 3877 results for "".
The Rising Costs of Prescription Drugs
https://practicaldermatology.com/topics/practice-management/the-rising-costs-or-prescription-drugs/18677/What's really causing the costs of dermatology prescriptions, especially generics, to skyrocket? Jake Levitt, MD and Mark Lebwohl, MD speak to host Neal Bhatia, MD about what's influencing these rising costs, and who, if anyone, is benefiting. Dr. Levitt talks about the rebate system between manufacA Happy and Productive Staff
https://practicaldermatology.com/topics/practice-management/a-happy-and-productive-staff/19080/Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions have the secrets for happy and productive staff--and improved efficiency for your practice.Update on Keloids and Scarring
https://practicaldermatology.com/topics/general-topics/update-on-keloids-and-scarring/19267/Brian Berman, MD talks with host Joshua Zeichner, MD about the use of interferon and topical immune modulators for the management of keloids. What does the evidence show? What are optimal protocols?Psoriasis: Guidelines and Clinical Pearls
https://practicaldermatology.com/topics/general-topics/psoriasis-guidelines-and-clinical-pearls/19339/Psoriasis specialist Jerry Bagel, MD speaks with host Joshua Zeichner, MD about new Treatment Guidelines, their impact on clinical decision making, and his own approach to patient care. Watch now for tips on patient management and treatment selection. Bonus Material: Dr. Bagel addresses the subjectThe Biggest Developments in Dermatology: Drs. Tsao and Friedlander Provide Updates at Maui Derm
https://practicaldermatology.com/issues/january-february-2025/the-biggest-developments-in-dermatology-drs-tsao-and-friedlander-provide-updates-at-maui-derm/32937/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, adopted a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Part 6, 1726 nm lasers: Growing the market for the 1726 nm wavelength lasers
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24344/Chapter 6 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the growing the market for the 1726 nm wavelength lasers."Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leThe PA Salary: Structures and Strategies
https://practicaldermatology.com/topics/general-topics/the-pa-salary-structures-and-strategies/21597/Just as there is a wide range of practice settings that utilize a PA, there is an array of salary structures for PAs. Choose a structure that is fair and mutually beneficial.Long-Term Bimzelx Data Presented
https://practicaldermatology.com/series/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/series/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discusses